Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials

Abstract

Objective

In this study, we aimed to assess the relative efficacy and safety of intravenous (IV) or subcutaneous (SC) belimumab compared with those of placebo in patients with active systemic lupus erythematosus (SLE).

Methods

We performed a Bayesian network meta-analysis to combine the direct and indirect evidence from randomized controlled trials (RCTs) examining the efficacy and safety of belimumab 1 mg/kg and 10 mg/kg IV administration, and belimumab 200 mg SC injection, and placebo in patients with active SLE despite having received standard therapy.

Results

Five RCTs (3460 patients) met the inclusion criteria. The SLE Responder Index (SRI) response rate at week 52 was significantly higher in the belimumab 10 mg/kg group than in the placebo group (OR 2.63, 95% CrI 2.14–3.23). Similarly, the SRI response rates were significantly higher in the belimumab 1 mg/kg, and belimumab 200 mg SC groups than in the placebo group (OR 2.42, 95% CrI 1.90–3.09; OR 1.71, 95% CrI 1.27–2.29). Ranking probability based on surface under the cumulative ranking curve (SUCRA) indicated that belimumab 10 mg/kg had the highest probability of being the best treatment for achieving the SRI response (SUCRA = 0.9174), followed by belimumab 1 mg/kg (SUCRA = 0.7338), belimumab 200 mg SC (SUCRA = 0.3487), and placebo (SUCRA = 0.0000). However, a sensitivity test by omitting one outlier study showing low SRI response rate compared with the other three studies (11% vs. 33%, 40%, 48%) showed that belimumab 200 mg SC and belimumab 10 mg/kg had the highest probability of being the best treatment for achieving the SRI response (SUCRA = 0.7903, SUCRA = 0.7456), followed by belimumab 1 mg/kg, and placebo. The number of serious adverse events (SAEs) did not differ significantly among the four treatment options.

Conclusions

Belimumab at 1 and 10 mg/kg IV and belimumab 200 mg SC in combination with standard therapy was an efficacious intervention for active SLE, and was not associated with a significant risk of SAEs.

Keywords

Belimumab systemic lupus erythematosus network meta-analysis

Get full access to this article

View all access options for this article.

References

Ruiz-Irastorza

Khamashta

Castellino

Hughes

. Systemic lupus erythematosus. Lancet 2001; 357(9261): 1027–1032.

Dörner

Giesecke

Lipsky

. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011; 13(5): 1–1.

Vincent

Saulep-Easton

Figgett

Fairfax

Mackay

. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013; 24(3): 203–215.

Day

Cachero

Qian

et al.

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005; 44(6): 1919–1931.

Mackay

Woodcock

Lawton

et al.

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190(11): 1697–1710.

Ramanujam

Bethunaickan

Huang

Tao

Madaio

Davidson

. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010; 62(5): 1457–1468.

Jordan

D’Cruz

. Current and emerging treatment options in the management of lupus. Immunotargets Ther 2016; 5: 9–20.

Baker

Edwards

Main

et al.

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48(11): 3253–3265.

Halpern

Lappin

Zanardi

et al.

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006; 91(2): 586–599.

10.

Navarra

Guzmán

Gallacher

et al.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377(9767): 721–731.

11.

Furie

Petri

Zamani

et al.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63(12): 3918–3930.

12.

Wallace

Stohl

Furie

et al.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res 2009; 61(9): 1168–1178.

13.

Zhang

Bae

Bass

et al.

A pivotal phase III, randomized, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan, and South Korea [abstract]. Arthritis Rheumatol 2016; 68(suppl 10): 742–742.

14.

Wei

L-Q

Liang

Y-G

Zhao

Liang

H-T

Qin

D-C

She

M-C

. Efficacy and safety of belimumab plus standard therapy in patients with systemic lupus erythematosus: A meta-analysis. Clin Ther 2016; 38(5): 1134–1140.

15.

Kandala

N-B

Connock

Grove

et al.

Belimumab: A technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open 2013; 3(7): e002852–e002852.

16.

Lee

. Overview of network meta-analysis for a rheumatologist. J Rheum Dis 2016; 23(1): 4–10.

17.

Furie

Petri

Wallace

et al.

Novel evidence-based systemic lupus erythematosus responder index. Arthritis Care Res 2009; 61(9): 1143–1151.

18.

Jadad

Moore

Carroll

et al.

Assessing the quality of reports of randomized clinical trials: Is blinding necessary?

Control Clin Trials 1996; 17(1): 1–12.

19.

Moher

Liberati

Tetzlaff

Altman

. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151(4): 264–229.

20.

Brown

Hutton

Clifford

et al.

A Microsoft-Excel-based tool for running and critically appraising network meta-analyses – an overview and application of NetMetaXL. Syst Rev 2014; 3(1): 110–110.

21.

Caldwell

Ades

Higgins

. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ 2005; 331(7521): 897–897.

22.

Salanti

Ades

Ioannidis

. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J Clin Epidemiol 2011; 64(2): 163–171.

23.

Dias

Welton

Sutton

Caldwell

Ades

. Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013; 33(5): 641–656.

24.

Higgins

Jackson

Barrett

Ades

White

. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res Synth Methods 2012; 3(2): 98–110.

25.

Valkenhoef

Brock

Hillege

Ades

Welton

. Automating network meta-analysis. Res Synth Methods 2012; 3(4): 285–299.

26.

Wallace

Navarra

Petri

et al.

Safety profile of belimumab: Pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013; 22(2): 144–154.

27.

van Vollenhoven

Petri

Cervera

et al.

Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Ann Rheum Dis 2012; 71(8): 1343–1349.

28.

Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study. Arthritis Rheumatol 2017.

29.

Schneider

MacKay

Steiner

et al.

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189(11): 1747–1756.

30.

Vincent

Morand

Schneider

Mackay

. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10(6): 365–373.

31.

Vilas-Boas

Morais

Isenberg

. Belimumab in systemic lupus erythematosus. RMD Open 2015; 1(1): e000011–e000011.